Core Viewpoint - The innovation drug sector in the A-share and Hong Kong markets is experiencing significant fluctuations, with notable movements in ETFs focused on innovative drug development, indicating strong capital inflows and market interest [1][3]. Group 1: ETF Performance - The A-share innovation drug ETF (562050) fell by 0.61%, ending a two-day rise, while the Hong Kong innovation drug ETF (520880) briefly rose over 1% before closing down 0.15% [1]. - The Hong Kong innovation drug ETF (520880) has seen premium trading, with over 5.1 billion yuan invested last week, reflecting strong demand [1][3]. Group 2: Component Stock Performance - Significant divergence in performance among major component stocks of the Hong Kong innovation drug ETF, with notable gains from companies like Shijiazhuang Pharmaceutical Group and Hansoh Pharmaceutical, while companies like Innovent Biologics faced declines [3]. - New component stocks have shown remarkable performance, with Yaojie Ankang-B surging by 115.58% and MIRXES-B and Ying'en Biotechnology-B rising by 25.91% and 13.18% respectively [3]. Group 3: Index Adjustments - The Hong Kong innovation drug ETF (520880) underwent a "purification" adjustment on September 8, removing CXO companies and focusing solely on 14 innovative drug development firms, enhancing its representation of the sector [4]. - The adjusted index aims to provide a more accurate reflection of the performance of China's innovative drug companies, with a focus on those solely engaged in drug development [4]. Group 4: Policy and Market Trends - Recent favorable policies, including a 30-day review channel for innovative drug clinical trial applications, are expected to accelerate drug development and enhance the quality of China's pharmaceutical industry [4][5]. - The domestic demand for innovative drugs is rising, transitioning from a "cash-burning" phase to becoming a "cash cow," indicating a shift towards sustainable revenue generation [5]. - Analysts suggest that the innovation drug sector remains a core focus within the pharmaceutical industry, with ongoing policy support and increasing global competitiveness [5].

Market Overview - The Shanghai Composite Index closed down 0.26% at 3860.5 points, while the ChiNext Index rose 1.51%, hitting a peak of 3% during the day [1] - A-shares saw a total trading volume of 2.3 trillion yuan, slightly lower than the previous day [1] Key Stocks and ETFs - CATL (Ningde Times) surged nearly 15% in early trading, closing up 9.14%, marking a historical high [1][6] - Related ETFs such as the Smart Electric Vehicle ETF (516380) and Green Energy ETF (562010) rose over 4% during the day [1] - The Smart Electric Vehicle ETF closed up 2.93%, reaching a new high since August 2022 [6] Policy and Industry Developments - The "New Energy Storage Scale Construction Special Action Plan (2025-2027)" was issued, aiming for a national new energy storage capacity of over 180 GW by 2027, with direct investment expected to reach approximately 250 billion yuan [1] - The automotive sector is expected to see a significant increase in sales, with a target of 32.3 million vehicles in 2025, including 15.5 million new energy vehicles [10] Performance of Specific Stocks - Key stocks in the battery sector, such as Tianqi Lithium and Hunan YN, saw increases of over 10% and 9.99% respectively [8][9] - The automotive sector also performed well, with companies like Junsheng Electronics and Top Group rising over 6% [8] Hong Kong Market Insights - The Hong Kong market showed independent performance with the Hang Seng Index and Hang Seng Tech Index both closing up [3] - The Hong Kong Internet ETF (513770) has seen significant inflows, with a net inflow of 7.9 billion yuan last week [17][20] Future Expectations - The upcoming Federal Reserve interest rate decision is anticipated to improve liquidity conditions, potentially benefiting the Hong Kong market, especially in technology and innovative pharmaceutical sectors [5][20] - The Smart Electric Vehicle ETF is expected to continue benefiting from policies supporting electric vehicle and battery technology advancements [10][11]

Core Viewpoint - The approval of ALMB-0166 for Phase II clinical trials in China represents a significant advancement in the treatment of Parkinson's disease, addressing a critical need for new therapies in this area [1][2]. Group 1: Company Developments - The company has received approval from the National Medical Products Administration of China to conduct Phase II clinical trials for ALMB-0166, a first-in-class humanized monoclonal antibody inhibitor targeting the novel target Connexin43 (Cx43) [1]. - ALMB-0166 is developed by the company's subsidiary, AlaMab Therapeutics Inc., and is intended for treating neurological diseases such as Parkinson's disease, acute ischemic stroke, and acute spinal cord injury [1]. Group 2: Industry Context - Parkinson's disease is the second most common neurodegenerative disease globally, characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies [2]. - Current treatments, primarily based on levodopa, only alleviate symptoms without reversing disease progression or achieving a cure, highlighting the urgent need for new therapeutic options [2]. - ALMB-0166 targets Cx43 hemichannels to inhibit the release and spread of neuroinflammatory factors, thereby maximizing neuroprotection [2]. - Preclinical studies in subacute and chronic Parkinson's disease animal models have shown that ALMB-0166 significantly inhibits the reduction of dopamine levels in the brain and restores behavioral and functional abilities, demonstrating a favorable dose-response relationship [2]. Group 3: Future Plans - The company is committed to advancing the clinical research of ALMB-0166 across various indications, aiming for its expedited market launch [3].

Core Viewpoint - The company has received approval from the National Medical Products Administration of China to conduct Phase II clinical trials for ALMB-0166, a first-in-class humanized monoclonal antibody inhibitor targeting the novel target Connexin43 (Cx43), aimed at treating Parkinson's disease [1][2]. Group 1: Product Development - ALMB-0166 is developed by the company's subsidiary, AlaMab Therapeutics Inc., and is intended for treating neurological diseases such as Parkinson's disease, acute ischemic stroke, and acute spinal cord injury [1]. - The company is committed to advancing clinical research for ALMB-0166 across various indications, aiming for its swift market launch [3]. Group 2: Parkinson's Disease Context - Parkinson's disease is the second most common neurodegenerative disease globally, characterized by the progressive degeneration of dopamine neurons in the substantia nigra and the formation of Lewy bodies [2]. - Current treatments, primarily centered around levodopa, only alleviate symptoms without reversing disease progression or achieving a cure, highlighting the urgent need for new therapeutic options [2]. - ALMB-0166 targets Cx43 hemichannels to inhibit the release and spread of neuroinflammatory factors, thereby maximizing neuroprotection [2]. - Preclinical studies in subacute and chronic Parkinson's disease animal models have shown that ALMB-0166 significantly inhibits the reduction of dopamine levels in the brain and restores behavioral and functional capabilities, demonstrating a favorable dose/effect relationship [2].

Core Viewpoint - The approval of ALMB-0166 for Phase II clinical trials in China represents a significant advancement in the treatment of Parkinson's disease, addressing a critical need for new therapies in this area [1][2]. Group 1: Company Developments - The company, Shiyao Group, has announced that its developed drug ALMB-0166 has received approval from the National Medical Products Administration of China to conduct Phase II clinical trials for evaluating its efficacy in patients with Parkinson's disease [1]. - ALMB-0166 is a first-in-class humanized monoclonal antibody inhibitor targeting the novel target Connexin 43 (Cx43), developed by the company's subsidiary, AlaMab Therapeutics Inc. [1]. - The company is committed to advancing the clinical research of ALMB-0166 across various indications, aiming for its swift market launch [3]. Group 2: Industry Context - Parkinson's disease is the second most common neurodegenerative disease globally, characterized by the progressive degeneration of dopamine neurons in the substantia nigra and the formation of Lewy bodies [2]. - Current treatments, primarily based on levodopa, only alleviate symptoms without reversing disease progression or achieving a cure, highlighting the urgent need for new therapeutic options [2]. - ALMB-0166 targets Cx43 hemichannels to inhibit the release and spread of neuroinflammatory factors, maximizing neuroprotection, and preclinical studies have shown significant efficacy in preserving dopamine levels and restoring behavioral functions in animal models [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 主席 ALMB -0166為一款同類首創（ First-in-class ）針對全新靶點半通道膜蛋白Connexin 43 (Cx43)的 人源化單克隆抗體抑制劑，由本公司附屬公司AlaMab Therapeutics Inc.自主研發，用於治療 帕金森氏症、急性缺血性腦卒中、急性脊髓損傷等神經系統疾病。 帕金森氏症是全球第二大神經退行性疾病，以黑質多巴胺神經元進行性退變和路易小體形 成為主要病理特徵。帕金森氏症的病因迄今尚未完全明確，臨床表現以靜止性震顫、肌強 直、動作遲緩、姿勢平衡障礙的運動症狀和睡眠障礙、認知和精神障礙等非運動症狀為顯 著特徵。其運動和非運動症狀會隨疾病進展逐漸加重，嚴重影響患者的生活質量，並給家 庭和社會帶來沉重的經濟與 ...

Core Viewpoint - The recent market turbulence in the innovative drug sector is attributed to reports of a potential executive order from the Trump administration, which aims to impose stricter reviews on U.S. companies acquiring Chinese innovative drugs and increase FDA scrutiny on Chinese clinical trial data [1][5]. Group 1: Market Reaction - After an initial drop of over 4% in the innovative drug sector index and a 7% decline in the Hang Seng Biotech Index, market panic subsided quickly [2]. - Analysts believe the likelihood of the executive order being implemented is low, suggesting that the immediate impact on innovative drug business development (BD) will be limited and primarily emotional [3][7]. Group 2: Implications of the Executive Order - The proposed executive order includes stricter reviews by the Committee on Foreign Investment in the United States (CFIUS) for U.S. multinational pharmaceutical companies acquiring pipelines from Chinese firms [5]. - In the first half of this year, the total value of BD transactions for Chinese innovative drugs reached nearly $66 billion, with projections indicating that by 2040, 35% of new drugs approved by the FDA could originate from China [5][6]. Group 3: Competitive Landscape - The executive order reflects a conflict between U.S. biotech companies, which lobby for restrictions, and multinational corporations (MNCs) that benefit from acquiring overseas assets [6]. - By 2035, $115 billion worth of drug patents will expire in Europe and the U.S., necessitating MNCs to seek new pipelines, with Chinese assets being a favorable option due to their quality and cost [6]. Group 4: Clinical Trial Data Scrutiny - The FDA's stricter scrutiny of clinical trial data from Chinese patients is seen as unlikely to change the current landscape, as the FDA has already been tightening its review processes [8][10]. - The high costs associated with conducting clinical trials abroad compared to domestic trials lead many Chinese firms to retain domestic rights while transferring overseas rights to MNCs [9]. Group 5: Future Outlook - Despite the potential for political interference, analysts believe there remains a 5-10 year window of opportunity for BD transactions, driven by the high demand from large pharmaceutical companies [11][12]. - The recent surge in large BD deals indicates a shift in perception regarding the value of Chinese assets, moving away from the notion of "selling assets cheap" to recognizing their quality and efficiency [13][14].

Core Viewpoint - The article discusses the emergence of a new investment paradigm in China's innovative pharmaceutical sector, exemplified by the first "Fusion NewCo" model, which emphasizes the importance of small, efficient teams in driving innovation and the role of local capital in accelerating development [2][3]. Group 1: NewCo Model - The "NewCo" model is designed to facilitate rapid market entry for innovative drugs by involving investment institutions from the outset, focusing on value verification and global transactions [3][5]. - The recent establishment of the first domestic "Fusion NewCo" by Hongyi Investment and Aikou Lian Bio signifies a shift where local capital begins to dominate the value release pathway for Chinese innovative drugs [3][5]. Group 2: Market Dynamics - The Chinese innovative drug sector is transitioning from an "introduction" phase to a "leadership" phase in global markets, driven by unique advantages in research efficiency and cost [5][9]. - Data indicates that Phase I clinical trials in China can be completed 25% to 55% faster than in overseas companies, with costs only 30% to 50% of multinational corporations (MNCs) [5][9]. Group 3: Investment Strategy - Hongyi Investment's strategy focuses on leveraging local resources and optimizing asset allocation to capture investment opportunities in innovative drugs [9][10]. - The company aims to establish a "NewCo Plus platform + fund" model, which integrates top scientists, efficient clinical operations, and international business development channels to create a robust ecosystem for innovation [10][11]. Group 4: Future Outlook - The "NewCo Plus" model is expected to evolve into a Hub-and-Spoke structure, allowing for centralized resource management and enabling multiple NewCos to focus on technological breakthroughs [11][12]. - This approach is anticipated to significantly reduce the time required for innovative drugs to reach market readiness, enhancing capital turnover rates for investors [11][12].

Group 1 - The core viewpoint of the news is that the innovative drug industry in China is experiencing significant policy support, which is expected to enhance the international competitiveness of domestic innovative drugs [1][2] - The National Medical Products Administration (NMPA) has officially launched a 30-day review and approval channel for innovative drug clinical trials, which will expedite the approval process for eligible applications [1][2] - The new policies are expected to shorten the clinical trial initiation cycle by approximately 30%-50%, particularly benefiting high-investment fields such as cell and gene therapy [2] Group 2 - As of September 12, 2025, the innovative drug ETF tracking major companies in the sector has shown a significant increase in value, with a PE-TTM of 27.5 times, indicating over 60% potential for recovery from historical peaks [3] - The innovative drug sector in China has seen a rise in the number of drugs under development, accounting for over 20% of the global total, positioning China as the second-largest in new drug research and development [2] - The core competitive advantages of Chinese innovative drugs include a significant engineer dividend and efficient implementation capabilities in advanced fields such as ADC, cell therapy, and gene therapy [2]

Market Performance - The Hang Seng Healthcare Index increased by 0.76%, with notable gains from companies such as Baize Medical (+54.41%) and Brainstorm Aurora-B (+34.40%) [3] - The Hang Seng Healthcare ETF (513060) rose by 1.08%, with a recent price of 0.75 yuan, and has accumulated a 4.96% increase over the past two weeks, ranking in the top third among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index saw a 0.26% rise, with significant increases from companies like Yaojie Ankang-B (+42.96%) and MIRXES-B (+28.86%) [3] Liquidity and Trading Activity - The Hang Seng Healthcare ETF had a turnover rate of 21.64% and a trading volume of 1.586 billion yuan, indicating active market participation [3] - The Hong Kong Stock Connect Innovative Drug Selection ETF recorded a turnover rate of 27.79% and a trading volume of 105 million yuan, also reflecting a vibrant trading environment [4] Policy and Industry Developments - The State Council reviewed and approved the draft regulations for the management of clinical research and clinical application of biomedical new technologies, emphasizing the dual focus on innovation and safety [5] - The CSCO conference highlighted the rapid rise of China's clinical capabilities, with more Chinese experts becoming principal investigators in global studies, showcasing the international influence of China's innovative drug clinical research [5] Institutional Insights - The combination of supportive policies and international clinical integration is expected to catalyze the full industry chain development of domestic innovative drugs [6] - Companies with global clinical design and MRCT capabilities are likely to capture market share, despite potential review risks from stricter FDA policies [6] Related ETFs - The Hang Seng Healthcare ETF (513060) tracks the Hang Seng Healthcare Index, covering core assets in Hong Kong's healthcare sector [7] - The Hong Kong Stock Connect Innovative Drug Selection ETF (520690) closely follows the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, focusing on leading innovative drug companies [8]